<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179751</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-PANC-001</org_study_id>
    <nct_id>NCT00179751</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas</brief_title>
  <official_title>A Phase I/II Study Of Lenalidomide (Revlimid ) In Combination With Gemcitabine In Patients With Untreated Advanced Carcinoma Of The Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prologue Research International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <brief_summary>
    <textblock>
      Phase I will determine the MDT and evaluate the safety profile of oral lenalidomide days 1-21&#xD;
      and weekly gemcitabine days 1, 8, &amp; 15 in 28 day cycles Phase II will explore the anti-tumor&#xD;
      activity and safety of the combination in subjects with advanced pancreatic carcinoma.&#xD;
      Subjects will receive oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, &amp; 15 in&#xD;
      28 day cycles until documented disease progression occurs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>August 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I-To determine the maximum tolerated dose (MTD) and evaluate the safety profile of oral lenalidomide days 1- 21 in combination with gemcitabine days 1, 8, and 15 every 28 days in subjects with advanced pancreatic carcinoma.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II-To explore the anti-tumor activity of the combination of lenalidomide on days 1 - 21 and gemcitabine days 1, 8, and 15 every 28 days in subjects with advanced pancreatic carcinoma.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I-To explore the anti-tumor activity of the combination of lenalidomide and gemcitabine as combination therapy in subjects with advanced pancreatic carcinoma.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II-To evaluate the safety profile of the combination of lenalidomide and gemcitabine as combination therapy in subjects with advanced pancreatic carcinoma.</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-5013</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must understand and voluntarily sign an informed consent document.&#xD;
&#xD;
          2. Age &gt;or = to 18 years at the time of signing informed consent form.&#xD;
&#xD;
          3. Subjects must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
          4. Histological documentation of advanced pancreatic carcinoma not amenable to curative&#xD;
             surgery or definitive radiation.&#xD;
&#xD;
          5. Radiographic or clinical evidence of measurable advanced pancreatic carcinoma.&#xD;
             Subjects must have measurable disease at least 2 cm in diameter.&#xD;
&#xD;
          6. Subjects may have been previously treated with radiation therapy and 5-fluorouracil as&#xD;
             a radiosensitizer in the adjuvant setting if they currently have evidence of&#xD;
             progression.&#xD;
&#xD;
          7. ECOG performance status of 0 or 1 (Appendix I: ECOG Performance Status Scale).&#xD;
&#xD;
          8. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy&#xD;
             test within 7 days of starting study drug. In addition, sexually active WCBP must&#xD;
             agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal&#xD;
             contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with&#xD;
             spermicide; or vasectomized partner) while on study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following laboratory abnormalities:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt;1,500 cells/mm3 (1.5 x 109/L)&#xD;
&#xD;
               2. Platelet count &lt;100,000 cells/mm3 (100 x 109/L)&#xD;
&#xD;
               3. Serum creatinine &gt;2.5 mg/dL (221 mmol/L)&#xD;
&#xD;
               4. Serum SGOT/AST or SGPT/ALT &gt;3.0 x upper limit of normal (ULN)&#xD;
&#xD;
               5. Serum total bilirubin &gt;2.0 mg/dL (34 mmol/L)&#xD;
&#xD;
          2. Any serious medical condition or psychiatric illness that places the subject at an&#xD;
             unacceptable risk for study participation or would prevent the subject from signing&#xD;
             the informed consent.&#xD;
&#xD;
          3. Prior history of malignancy (except basal cell or squamous cell carcinoma or carcinoma&#xD;
             in situ of the breast) unless the subject has been free of disease for &gt; or = to 1&#xD;
             year.&#xD;
&#xD;
          4. Known brain or leptomeningeal disease (CT scan or MRI of the brain required only in&#xD;
             case of clinical suspicion of central nervous system involvement).&#xD;
&#xD;
          5. Prior use of systemic therapy for the treatment of carcinoma of the pancreas with the&#xD;
             exception of 5-fluorouracil as a radiosensitizer in the adjuvant setting.&#xD;
&#xD;
          6. Concurrent use of any other anti-cancer agents.&#xD;
&#xD;
          7. Any prior use of lenalidomide.&#xD;
&#xD;
          8. Prior &gt; or = to grade 3 (see Appendix III) allergic reaction/hypersensitivity to&#xD;
             thalidomide.&#xD;
&#xD;
          9. Prior &gt; or = to grade 3 (see Appendix III) rash or any desquamating (blistering) rash&#xD;
             while taking thalidomide.&#xD;
&#xD;
         10. Use of any standard/experimental anti-cancer drug therapy within 28 days of the&#xD;
             initiation of study drug therapy.&#xD;
&#xD;
         11. Pregnant or lactating females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer and Blood Institute</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernard Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University Hospitals Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203-1632</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2005</verification_date>
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>November 2, 2005</last_update_submitted>
  <last_update_submitted_qc>November 2, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2005</last_update_posted>
  <keyword>cc-5013</keyword>
  <keyword>revlimid</keyword>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

